New Strategies for Alzheimer Disease and Cognitive Impairment

Approximately five million people suffer with Alzheimer disease (AD) and more than twenty‐four million people are diagnosed with AD, pre‐senile dementia, and other disorders of cognitive loss worldwide. Furthermore, the annual cost per patient with AD can approach $200,000 with an annual population...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oxidative medicine and cellular longevity 2009-11, Vol.2 (5), p.279-289
Hauptverfasser: Maiese, Kenneth, Chong, Zhao Zhong, Hou, Jinling, Shang, Yan Chen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Approximately five million people suffer with Alzheimer disease (AD) and more than twenty‐four million people are diagnosed with AD, pre‐senile dementia, and other disorders of cognitive loss worldwide. Furthermore, the annual cost per patient with AD can approach $200,000 with an annual population aggregate cost of $100 billion. Yet, complete therapeutic prevention or reversal of neurovascular injury during AD and cognitive loss is not achievable despite the current understanding of the cellular pathways that modulate nervous system injury during these disorders. As a result, identification of novel therapeutic targets for the treatment of neurovascular injury would be extremely beneficial to reduce or eliminate disability from diseases that lead to cognitive loss or impairment. Here we describe the capacity of intrinsic cellular mechanisms for the novel pathways of erythropoietin and forkhead transcription factors that may offer not only new strategies for disorders such as AD and cognitive loss, but also function as biomarkers for disease onset and progression.
ISSN:1942-0900
1942-0994
DOI:10.4161/oxim.2.5.9990